These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21664307)

  • 1. Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS).
    Fischer JJ; Dalhoff C; Schrey AK; Graebner OY; Michaelis S; Andrich K; Glinski M; Kroll F; Sefkow M; Dreger M; Koester H
    J Proteomics; 2011 Dec; 75(1):160-8. PubMed ID: 21664307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
    Mashkani B; Griffith R; Ashman LK
    Bioorg Med Chem; 2010 Mar; 18(5):1789-97. PubMed ID: 20156689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of capture compound mass spectrometry technology (CCMS) for the profiling of human kinases by combination with 2D LC-MS/MS.
    Fischer JJ; Graebner O; Dreger M; Glinski M; Baumgart S; Koester H
    J Biomed Biotechnol; 2011; 2011():850589. PubMed ID: 21941435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteome-wide identification of staurosporine-binding kinases using capture compound mass spectrometry.
    Fischer JJ; Graebner Neé Baessler OY; Dreger M
    Methods Mol Biol; 2012; 795():135-47. PubMed ID: 21960220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive identification of staurosporine-binding kinases in the hepatocyte cell line HepG2 using Capture Compound Mass Spectrometry (CCMS).
    Fischer JJ; Graebner Baessler OY; Dalhoff C; Michaelis S; Schrey AK; Ungewiss J; Andrich K; Jeske D; Kroll F; Glinski M; Sefkow M; Dreger M; Koester H
    J Proteome Res; 2010 Feb; 9(2):806-17. PubMed ID: 20028079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
    Kitagawa D; Gouda M; Kirii Y; Sugiyama N; Ishihama Y; Fujii I; Narumi Y; Akita K; Yokota K
    J Biochem; 2012 Jan; 151(1):47-55. PubMed ID: 21880693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
    Birch M; Morgan PE; Handley S; Ho A; Ireland R; Flanagan RJ
    Biomed Chromatogr; 2013 Mar; 27(3):335-42. PubMed ID: 22886846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
    de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
    Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.
    Schrage YM; Briaire-de Bruijn IH; de Miranda NF; van Oosterwijk J; Taminiau AH; van Wezel T; Hogendoorn PC; Bovée JV
    Cancer Res; 2009 Aug; 69(15):6216-22. PubMed ID: 19602594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GDP-capture compound--a novel tool for the profiling of GTPases in pro- and eukaryotes by capture compound mass spectrometry (CCMS).
    Luo Y; Fischer JJ; Baessler OY; Schrey AK; Ungewiss J; Glinski M; Sefkow M; Dreger M; Koester H
    J Proteomics; 2010 Feb; 73(4):815-9. PubMed ID: 20026263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
    Bantscheff M; Eberhard D; Abraham Y; Bastuck S; Boesche M; Hobson S; Mathieson T; Perrin J; Raida M; Rau C; Reader V; Sweetman G; Bauer A; Bouwmeester T; Hopf C; Kruse U; Neubauer G; Ramsden N; Rick J; Kuster B; Drewes G
    Nat Biotechnol; 2007 Sep; 25(9):1035-44. PubMed ID: 17721511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
    Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
    Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tuned affinity-based staurosporine probe for in situ profiling of protein kinases.
    Cheng X; Li L; Uttamchandani M; Yao SQ
    Chem Commun (Camb); 2014 Mar; 50(22):2851-3. PubMed ID: 24496501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Future Oncol; 2006 Dec; 2(6):655-65. PubMed ID: 17155893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes.
    Shi H; Zhang CJ; Chen GY; Yao SQ
    J Am Chem Soc; 2012 Feb; 134(6):3001-14. PubMed ID: 22242683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer.
    Lee JG; McKinney KQ; Mougeot JL; Bonkovsky HL; Hwang SI
    Proteomics; 2013 Dec; 13(23-24):3554-62. PubMed ID: 24167056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation.
    Reddiconto G; Chiusolo P; Fiorini A; Farina G; Sorà F; Leone G; Sica S
    Leuk Lymphoma; 2007 Oct; 48(10):2054-7. PubMed ID: 17917973
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.